WO2020008442A3 - Biopharmaceutical agents for use in reducing lipid content in cells - Google Patents

Biopharmaceutical agents for use in reducing lipid content in cells Download PDF

Info

Publication number
WO2020008442A3
WO2020008442A3 PCT/IB2019/055788 IB2019055788W WO2020008442A3 WO 2020008442 A3 WO2020008442 A3 WO 2020008442A3 IB 2019055788 W IB2019055788 W IB 2019055788W WO 2020008442 A3 WO2020008442 A3 WO 2020008442A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid content
cells
biopharmaceutical agent
biopharmaceutical
kda
Prior art date
Application number
PCT/IB2019/055788
Other languages
French (fr)
Other versions
WO2020008442A2 (en
Inventor
Stefan Franz Thomas Weiss
Tyrone Chad OTGAAR
Eloise VAN DER MERWE
Martin BERNERT
Gavin Morris
Original Assignee
University Of The Witwatersrand, Johannesburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of The Witwatersrand, Johannesburg filed Critical University Of The Witwatersrand, Johannesburg
Priority to CN201980055207.XA priority Critical patent/CN112601540A/en
Priority to US17/258,217 priority patent/US20210277084A1/en
Priority to EP19768889.8A priority patent/EP3817764B1/en
Publication of WO2020008442A2 publication Critical patent/WO2020008442A2/en
Publication of WO2020008442A3 publication Critical patent/WO2020008442A3/en
Priority to ZA2021/00684A priority patent/ZA202100684B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Abstract

This disclosure relates to a biopharmaceutical agent including a 37 kDa/67 kDa laminin receptor precursor/ high affinity laminin receptor (LRP/LR) and/or a fragment thereof for use treatment and/or prevention of atherosclerosis and/or obesity and/or insulin resistance and/or diabetes. The biopharmaceutical agent may be encapsulated by functionalized or non-functionalized nanoparticles, and further may be formulated to include a carrier to provide a pharmaceutical composition for parental or non-parental administration. In use, the biopharmaceutical agent reduces lipid content in target cells. The disclosure also relates to a method of decreasing lipid concentration in a target cell of a human or animal subject.
PCT/IB2019/055788 2018-07-06 2019-07-08 Biopharmaceutical agents for use in reducing lipid content in cells WO2020008442A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201980055207.XA CN112601540A (en) 2018-07-06 2019-07-08 Biopharmaceuticals for reducing lipid content in cells
US17/258,217 US20210277084A1 (en) 2018-07-06 2019-07-08 Biopharmaceutical agents for use in reducing lipid content in cells
EP19768889.8A EP3817764B1 (en) 2018-07-06 2019-07-08 Biopharmaceutical agents for use in reducing lipid content in cells
ZA2021/00684A ZA202100684B (en) 2018-07-06 2021-01-29 Biopharmaceutical agents for use in reducing lipid content in cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ZA201804509 2018-07-06
ZA2018/04507 2018-07-06
ZA2018/04509 2018-07-06
ZA201804507 2018-07-06

Publications (2)

Publication Number Publication Date
WO2020008442A2 WO2020008442A2 (en) 2020-01-09
WO2020008442A3 true WO2020008442A3 (en) 2020-03-05

Family

ID=67953824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/055788 WO2020008442A2 (en) 2018-07-06 2019-07-08 Biopharmaceutical agents for use in reducing lipid content in cells

Country Status (5)

Country Link
US (1) US20210277084A1 (en)
EP (1) EP3817764B1 (en)
CN (1) CN112601540A (en)
WO (1) WO2020008442A2 (en)
ZA (1) ZA202100684B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220160824A1 (en) * 2018-11-28 2022-05-26 University Of The Witwatersrand, Johannesburg Compounds for use in the treatment of parkinson's disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015155383A (en) * 2014-02-19 2015-08-27 株式会社東洋新薬 Receptor expression promotor
WO2017077516A2 (en) * 2015-11-05 2017-05-11 University Of The Witwatersrand, Johannesburg Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
JP2018027935A (en) * 2016-08-10 2018-02-22 国立大学法人九州大学 67kda laminin receptor agonist and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140037574A1 (en) * 2010-11-26 2014-02-06 Pius Sedowhe Fasinu Pharmaceutical composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015155383A (en) * 2014-02-19 2015-08-27 株式会社東洋新薬 Receptor expression promotor
WO2017077516A2 (en) * 2015-11-05 2017-05-11 University Of The Witwatersrand, Johannesburg Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
JP2018027935A (en) * 2016-08-10 2018-02-22 国立大学法人九州大学 67kda laminin receptor agonist and use thereof

Also Published As

Publication number Publication date
WO2020008442A2 (en) 2020-01-09
EP3817764A2 (en) 2021-05-12
US20210277084A1 (en) 2021-09-09
CN112601540A (en) 2021-04-02
ZA202100684B (en) 2022-07-27
EP3817764B1 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
Sun et al. Modulation of microbiota-gut-brain axis by berberine resulting in improved metabolic status in high-fat diet-fed rats
Chan et al. Probiotic mixture VSL# 3 reduce high fat diet induced vascular inflammation and atherosclerosis in ApoE−/− mice
PH12015501009A1 (en) A composition for treating diabetes or diabesity comprising oxyntomodulin analog
WO2009109927A3 (en) Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
WO2010049678A3 (en) Treatment of energy utilization diseases
WO2007117661A3 (en) Drug microparticles
WO2010077883A3 (en) Antagonists of lysophosphatidic acid receptors
WO2007067616A3 (en) Uses of myostatin antagonists
CL2008001125A1 (en) COMPOUNDS DERIVED FROM PIRIMIDINONE CONDENSED WITH HETEROCICLES; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS DIABETES, METABOLIC SYNDROME AND OBESITY.
WO2007024700A8 (en) Exendin for treating diabetes and reducing body weight
NZ595021A (en) Treatment of diabetes and metabolic syndrome with enteral formulations of calcitonin peptides or calcitonin receptor agonists
CL2008001126A1 (en) COMPOUNDS DERIVED FROM PIRIMIDINONE CONDENSED WITH HETEROCICLES; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS DIABETES, METABOLIC SYNDROME AND OBESITY.
WO2011035335A3 (en) Stabilized liquid and lyophilized adamts13 formulations
WO2008027420A3 (en) Implantable devices for producing insulin
WO2007044591A3 (en) Vasoactive intestinal polypeptide pharmaceuticals
JP2016537410A5 (en)
WO2011141685A3 (en) Systemic nasal compositions comprising cocoyl proline or at least one of the constituents thereof
WO2005107773A8 (en) Solid dosage form of wetted heparin
MA33756B1 (en) Antifungal mixture with fungal organism Bitum oligdrum
WO2008147483A8 (en) Neurogenic compounds
WO2013109342A8 (en) Method of treating diabetes using non-glycosylated apolipoprotein a-iv
PH12014502802B1 (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2020008442A3 (en) Biopharmaceutical agents for use in reducing lipid content in cells
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
WO2012007913A3 (en) Oral administration forms for controlled release of rifampicin or other antibiotics for the treatment of bacterial infections and inflammatory diseases of the gastrointestinal tract

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19768889

Country of ref document: EP

Kind code of ref document: A2